Data Sheet (Cat.No.TMPY-02685)

TargetMol

ST6GALNAC2 Protein, Mouse, Recombinant (His)

General Information

Synonyms:	ST6GalNAc;II;ST6-N-acetylgalactosaminide α-2,6-sialyltransferase 2;Siat7;Siat7b;ST6-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2
Protein Construction:	A DNA sequence encoding the extracellular domain of mouse ST6GALNAC2 (P70277) (Ser 28-Arg 373) was expressed, with a C-terminal polyhistidine tag. Predicted N terminal: Ser 28
Species:	Mouse
Expression Host:	HEK293 Cells
Accession:	P70277
Molecular Weight:	40.7 kDa (predicted); 44 kDa (reducing conditions)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Reference

Li GS,et al.(2007) Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy. Hum Mutat. 28(10): 950-7.
Ding JX,et al.(2009) Activity of alpha2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy. Scand J Immunol. 69(2): 174-80.
Kiryluk K,et al.(2010) Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol. 25(11): 2257-68.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481